Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients - Full Text View

Sponsor:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00308802

Purpose

The purpose of this study is to test noninvasive methods to monitor the health and condition of new kidneys in people who have received kidney transplants.

Condition	Intervention
Kidney Transplantation	Procedure: Kidney transplantation

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant Recipients

Resource links provided by NLM:

MedlinePlus related topics: Kidney Transplantation

U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Biospecimen Retention: Samples With DNA

Blood samples may be retained

Estimated Enrollment:	300
Study Start Date:	March 2006
Estimated Study Completion Date:	July 2011

Intervention Details:

Participants in this study will have had a kidney transplant

Detailed Description:

Innovations in kidney transplantation have improved short-term outcomes for transplant patients. However, organ rejection remains as an important threat to the long-term survival of the transplanted organ. If clinicians could better monitor the condition of the organ after transplantation, they may be able to improve the chance of graft survival. Noninvasive ways to monitor the condition of the transplanted organ need to be developed and tested. This observational study will investigate whether certain blood and urine tests are useful in monitoring the health of transplanted kidneys.

This trial will involve 14 post-transplant study visits over the course of 2 years. A physical exam, medication history, adverse events assessment, and blood and urine collection will occur at all visits. Kidney biopsies will occur at study entry prior to transplantation and at Month 6, in adult participants only. Protocol biopsies are optional in the pediatric substudy group. Additional visits may be required if organ rejection is suspected.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

People who are candidates for kidney transplant

Criteria

Inclusion Criteria:

Candidate for deceased donor or living donor kidney transplant
Negative Crossmatch
Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

Clinically significant liver disease
Other illnesses that, in the opinion of the investigator, may interfere with the study
Recipient of multiple organ transplants
Inability or unwillingness to comply with the study protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00308802

Locations

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
Emory Children's Center
Atlanta, Georgia, United States, 30322
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44195
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Canada, Manitoba
University of Manitoba
Winnipeg, Manitoba, Canada, R3A 1R9
Children's Hospital of Winnipeg
Winnipeg, Manitoba, Canada, R3A 151

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

Study Director:	Peter S. Heeger, MD	Mount Sinai School of Medicine
Principal Investigator:	Donald Hricik, MD	University Hospitals of Cleveland
Principal Investigator:	David Rush, MD	University of Manitoba at Winnipeg
Principal Investigator:	Kenneth Newell, MD	Emory University
Principal Investigator:	Richard Formica, MD	Yale University
Principal Investigator:	Emilio Poggio, MD	The Cleveland Clinic
Principal Investigator:	Barry Warshaw, MD	Emory-Children's Center
Principal Investigator:	Enver Akalin, MD	Mount Sinai School of Medicine
Principal Investigator:	Patricia Birk, M.D.	Children's Hospital of Winnipeg

More Information

Additional Information:

Click here for the Clinical Trials in Organ Transplantation (CTOT) public Web site This link exits the ClinicalTrials.gov site

Publications:

Kaplan B, Srinivas TR, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther Drug Monit. 2002 Feb;24(1):36-9. Review.

Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004 Aug;4(8):1289-95.

Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.

Responsible Party:	Associate Director, Clinical Research Program, DAIT/NIAID
ClinicalTrials.gov Identifier:	NCT00308802 History of Changes
Other Study ID Numbers:	DAIT CTOT-01
Study First Received:	March 28, 2006
Last Updated:	July 2, 2010
Health Authority:	United States: Federal Government; United States: Institutional Review Board

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Kidney
Transplant
Rejection

Kidney Disease
Kidney Failure
End Stage Renal Disease

ClinicalTrials.gov processed this record on February 09, 2012